SRPT Today - Jul 15: Stock Slides Amid Pressure

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

SRPT Today - Jul 15: Stock Slides Amid Pressure

無料で聴く

ポッドキャストの詳細を見る

Hey there! It's Joey, your friendly investor buddy, here to break down what's up with Sarepta, or SRPT for short. Today was a bit rough, with the stock taking a dip of about 1.8%. Yeah, that one stung a bit.

So, what happened? Well, Sarepta shares got smoked as they faced some selling pressure. The stock had been riding a wave of excitement lately, especially with some buzz around FDA progress and new studies. But today, it just didn’t hold up. Volume was lower than usual too, which usually means folks were sitting on the sidelines, not wanting to jump in.

Now, let’s talk about the why. There’s been a lot of chatter about Sarepta being undervalued, especially with the FDA moving forward on their AMONDYS 45 and VYONDYS 53 therapies. These are big deals for the company and could really change the game for them. But despite that, some investors are feeling skittish. They might be worried about the overall market vibes or just looking for a reason to cash in some profits after the recent excitement. The stock slid about 4% earlier this week, which probably had some folks hitting that sell button today.

Oh, and here’s something to keep an eye on: Sarepta just kicked off enrollment for a new gene therapy safety study. That could be a big deal moving forward, especially if it brings some positive news down the line.

Anyway, that’s the scoop on SRPT today. It’s a wild ride in the stock market, but I’m here to keep you informed and entertained. Remember, this isn’t financial advice, just me sharing what I see. Catch you later!

まだレビューはありません